Navigation Links
OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Date:6/26/2012

SAN DIEGO, June 26, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced that Dr. Adil Daud, principal investigator, presented preliminary enrollment and safety data at the Second European Post-Chicago Melanoma Meeting in Munich, Germany for the company's on-going Phase II metastatic melanoma clinical trial, OMS-I100.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

To date, OMS-I100, a Phase II open-label, multi-center clinical trial investigating the safety and efficacy of plasmid interleukin-12 (DNA IL-12) with electroporation, has completed approximately 50 percent of enrollment. Based on currently available safety data, no grade three or higher adverse events related to the treatment have been reported, and most reported adverse events were treatable and transient.

Dr. Adil Daud said, "Interest in this study has been encouraging, and we expect to complete enrollment before the end of this year. We look forward to continuing follow-up of the patients that have been treated in order to measure any indication of a systemic immune response using DNA IL-12 and electroporation."

Punit Dhillon, President and CEO of OncoSec said, "Although preliminary, these results may validate the safety and tolerability of DNA IL-12 and electroporation that was demonstrated in the Phase I study." Mr. Dhillon added, "Following the design and implementation of our clinical development plan in 2011, we are pleased with the rapid enrollment for this study since initiation in February 2012, and believe it supports the adoption of the technology through our collaboration with leading academic institutions. We look forward to presenting an interim analysis of the clinical and immune response for this study late
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
5. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
6. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
9. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
10. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... VeraTag(TM) Assays in Breast ... Cancer, SOUTH ... announced five posters to be,presented at the 30th San Antonio Breast Cancer Symposium ... details for,each embargoed session:, -- Friday, December 14th, 2007, 7.00 am ...
... Biotech today announced that 12,clinical studies of DOXIL(R) ... the 49th annual meeting of the American Society ... on December 8-11,2007., "We are very pleased ... Craig Tendler, M.D., Vice President, Medical Affairs,Oncology/Nephrology, Ortho ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 2Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 4Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 5Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 6Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 7Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 8Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 9
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... much within a generation and nearly 1000 British women are ... issued a warning// that mixtures of chemicals present in day ... of breast cancer. ,Synthetic estrogens have caught the ... to the female sex hormone estrogen. Estrogen which is an ...
... taking the death toll in the capital to 33 Tuesday, ... the mosquito-borne viral disease showing no signs of abating. ... 83 new patients admitted in the city hospitals since Monday. ... 55-year-old Pritam of Faridabad town close to the national capital. ...
... Treatment outcomes vary widely and depend on which state, ... the finding of a new report//. ,The report, ... have a 69 percent lower risk of dying at ... the difference between the best- and worst-performing hospitals has ...
... needs this year according to state and federal officials who ... a shot. ,Annemarie Beardsworth, adult-immunization manager at the ... Rhode Island's public flu clinics, which started on Oct. 2, ... regular shipments. ,Beardsworth said, "Anyone who wants to ...
... United States researchers have explained the recent improvements in the ... slowing// the onset of paralysis. It is observed that people ... in charge of breathing actually stop working. Despite all the ... reasons that cause the disease. ,During the study, ...
... drug funding agency has confirmed that herceptin, a drug ... spite of ongoing criticism// over the decision. The deputy ... drug is highly expensive and funding could not be ... and has been arrived at after complete investigation of ...
Cached Medicine News:Health News:One More Victim Succumbs to Dengue in Delhi 2Health News:Hospital Outcome Linked to its Quality 2
... Injectable was designed to provide the surgeon with ... of surgical complications during cataract and retinal surgery. ... small and medium sized pupils which allows expansion ... iris sphincter during surgery, and allows the pupil ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
Provides stable positioning of the knee during surgery....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: